Description
Human CD33 Protein
| Catalog number: | B2011872 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 g |
| Molecular Weight or Concentration: | 1 mg/mL |
| Supplied as: | Solution |
| Applications: | molecular tool for various biochemical applications |
| Storage: | -20 C |
| Keywords: | CD33 molecule protein, FLJ00391 protein, p67 protein, SIGLEC-3 protein, SIGLEC3 protein |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Wifeld J, Nozaki I, Mathews M, Raschka T, Ebeling C, Hornung V, Brstle O, Neumann H. Deletion of Alzheimers disease-associated CD33 results in an inflammatory human microglia phenotype Glia. 2021 Jun;69(6):1393-1412.
- Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter DL, Carroll M, June CH, Gill S. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia Leukemia. 2015 Aug;29(8):1637-47.
- Wifeld J, Mathews M, Mossad O, Picardi P, Cinti A, Redaelli L, Pradier L, Brstle O, Neumann H. Reporter cell assay for human CD33 validated by specific antibodies and human iPSC-derived microglia Sci Rep. 2021 Jun 29;11(1):13462.
- DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs Blood. 2020 Jan 9;135(2):85-96.
- Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S. Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia Cell. 2018 May 31;173(6):1439-1453.e19.
- Tsai TY, Huang MT, Sung PS, Peng CY, Tao MH, Yang HI, Chang WC, Yang AS, Yu CM, Lin YP, Bau CY, Huang CJ, Pan MH, Wu CY, Hsiao CD, Yeh YH, Duan S, Paulson JC, Hsieh SL. SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection J Clin Invest. 2021 Jun 1;131(11):e141965.
- Willier S, Rothmel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy Blood. 2021 Feb 25;137(8):1037-1049.
- Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE. Alzheimers disease risk gene CD33 inhibits microglial uptake of amyloid beta Neuron. 2013 May 22;78(4):631-43.
- Griciuc A, Federico AN, Natasan J, Forte AM, McGinty D, Nguyen H, Volak A, LeRoy S, Gandhi S, Lerner EP, Hudry E, Tanzi RE, Maguire CA. Gene therapy for Alzheimers disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation Hum Mol Genet. 2020 Oct 10;29(17):2920-2935.
